読み込み中
NASDAQHealthcareBiotechnology
最新データ
$3.61
+$0.12 · +3.44%
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
前日終値
$3.61
+$0.12 · +3.44%
市場前
$3.53
−$0.08 · -2.22%
10月12日 7:15 ET
日中の時刻はETです。市場データは遅延する場合があります。
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
日中レンジ
現在 $3.61
52週レンジ
現在 $3.61
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
69
割安
センチメント
59
まちまち
リスク
66
高リスク
モメンタム
64
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
日中レンジ
現在 $3.61
52週レンジ
現在 $3.61
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 123.4万 USD | 13.5万 USD | — | — | — |
| 売上原価 | 5.3万 USD | — | — | — | — |
| 粗利益 | 118.1万 USD | 13.5万 USD | — | — | — |
| 研究開発 | 751.8万 USD | 910.5万 USD | 597.3万 USD | 250.3万 USD | 276.6万 USD |
| 販売・一般管理 | 583.8万 USD | 887.2万 USD | 803.7万 USD | 691.6万 USD | 168.3万 USD |
| 営業費用 | 1335.6万 USD | 1797.7万 USD | 1421万 USD | 1160.9万 USD | 444.9万 USD |
| 受取利息 | 32.5万 USD | 10.1万 USD | — | 630 USD | — |
| 支払利息 | 32.9万 USD | 24.4万 USD | 108.1万 USD | 63万 USD | 21.2万 USD |
| 減価償却費と償却費 | 1.8万 USD | — | 1401万 USD | — | — |
| 営業利益 | −1217.5万 USD | −1784.2万 USD | −1421万 USD | −1160.9万 USD | −444.9万 USD |
| 純利益 | −1215万 USD | −2483万 USD | −2623.2万 USD | −1219万 USD | −459.6万 USD |
会社概要が更新されました 2026年10月12日.
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$8.00
上昇余地（121.61%）この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
